MPN

There are promising drugs for myeloproliferative neoplasms coming down the pipeline.

View the full CURE Educated Patient MPN Summit on demand.

Blood cancer survivors are living longer than ever, making safe pain management an important concern.

Patients with a myeloproliferative neoplasm who smoked tended to have worse quality of life than those who did not.

CURE spoke with Dr. Rajiit Rampal, on behalf of the MPN Research Foundation, about MPN symptoms and their management.

CURE spoke with Brandon Goetzman, board member from the MPN Research Foundation, on elevating the patient’s voice when it comes to their care for myeloproliferative neoplasms.

CURE spoke with Dr. Gabriela Hobbs, on behalf of the MPN Research Foundation, about the need for clinical trial education for patients with myeloproliferative neoplasms.

CURE spoke with Dr. Rajiit Rampal, on behalf of the MPN Research Foundation, about disease progression in myeloproliferative neoplasms.

CURE spoke with Dr. Gabriela Hobbs, on behalf of the MPN Research Foundation, about currently available treatment options, as well as those under clinical investigation, for patients with myeloproliferative neoplasms.

Maintaining health before and after a diagnosis of myeloproliferative neoplasms could help patients as they undergo treatment.

Most research looked at the broad category of myeloid malignancies, not each individual disease.

Myeloproliferative neoplasms are rare in children. Here are some tips on navigating the uncertainty of a rare cancer diagnosis.

“There’s an infinite amount of information out there, but there’s not an infinite amount of quality information,” said an MPN expert.

Some patients with MPN in the UK were not prescribed the correct medications for management of specific diseases, highlighting the need for improvements in cardiovascular and thrombotic risk management.

The Geron Corporation announced that the first patient has been dosed with GRN163L — an experimental agent — in a phase 3 clinical trial to assess the drug’s overall survival benefit compared to best available therapy in patients with refractory myelofibrosis.

Treatment with daily Jakafi and parsaclisib improved spleen volume reduction and symptom burden in patients with myelofibrosis who had previously failed to achieve significant response to single-agent Jakafi.

Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.

At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects.

Of note, estimates show that there are more than 25,000 patients undergoing allogeneic hematopoietic cell transplantations throughout the United States and beyond. Recent study results show that these patients may be at a higher risk for de novo atrial fibrillation.

Watch our Myeloproliferative Neoplasms Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.

In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.

Watch the entire MPN Heroes program here!

Patients with myeloproliferative neoplasm (MPN) may benefit from this combination treatment if they are in the accelerated or blast phase of the disease.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ruben Mesa about understanding a myeloproliferative neoplasm diagnosis.